Roche : Invitation to Roche’s virtual event on key hematology data presented at ASH 2021

Investor Update

16 November 2021

Invitation to Roche's virtual event on key hematology data presented at ASH 2021

We are pleased to invite investors and analysts to participate in our virtual event on Wednesday, 15 December, 2021, highlighting Roche data presented at the virtual American Society of Hematology (ASH) 63rd Annual Meeting, from 11-14th December. 16:00 - 17:30 CET / 15:00 - 16:30 GMT 10:00 - 11:30 am EST / 7:00 - 8:30 am PST The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). Agenda: Welcome Karl Mahler, Head of Investor Relations Hematology franchise overview Peter Ahnesorg, Franchise Head Hematology Review of key clinical data presented at ASH: Hemlibra, mosun, glofit, cevostamab Charles Fuchs, Senior Vice President - Global Head Of Oncology And Hematology Product Development Presentation of POLARIX data Franck Morschhauser, MD, PhD, Professor of Hematology, University of Lille; President of LYSA, LYSARC Q&A The slides will be available for download at 15:00 CET on the day of the event. click here Access to virtual event (pre-registration required) Please pre-register for our webinar here*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to [e-mail]. A replay of the webcast will be available via ir.roche.com *privacy notice
Best regards, Karl Mahler Head of Investor Relations	Loren Kalm Head of Investor Relations, North America
Roche Investor Relations
Dr. Karl Mahler Phone: [phone] e-mail: [e-mail]	Dr. Sabine Borngräber Phone: [phone] e-mail: [e-mail]
Dr. Bruno Eschli Phone: [phone] e-mail: [e-mail]	Dr. Birgit Masjost Phone: [phone] e-mail: [e-mail]
Dr. Gerard Tobin Phone: [phone] e-mail: [e-mail]	Jon Kaspar Bayard Phone: [phone] e-mail: [e-mail]
Investor Relations North America
Loren Kalm Phone: [phone] e-mail: [e-mail]